0000070318false00000703182025-05-222025-05-220000070318exch:XNYSus-gaap:CommonStockMember2025-05-222025-05-220000070318exch:XNYSus-gaap:SeniorNotesMember2025-05-222025-05-22

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 _______________

FORM 8-K

 _______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report: May 22, 2025

(Date of earliest event reported)

 _______________

TENET HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

 

Nevada

1-7293

95-2557091

(State of Incorporation)

(Commission File Number)

(IRS Employer Identification Number)

 _______________

14201 Dallas Parkway

Dallas, TX 75254

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

 _______________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common stock, $0.05 par value

THC

NYSE

6.875% Senior Notes due 2031

THC31

NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

---

Item 5.07.			Submission of Matters to a Vote of Security Holders.

The 2025 Annual Meeting of Shareholders (the “Annual Meeting”) of Tenet Healthcare Corporation (the “Company”) was held on May 22, 2025. Below are the final voting results from the meeting.

1.    The Company’s shareholders elected the following directors to serve on the Company’s Board of Directors, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected or qualified, whichever is later, or until the director’s earlier resignation or removal:

						FOR						AGAINST						ABSTAIN						BROKER NON-VOTES
Saumya Sutaria						75,129,573						3,175,124						41,625						7,527,011
J. Robert Kerrey						76,518,701						1,792,925						34,696						7,527,011
Vineeta Agarwala						78,006,611						308,065						31,646						7,527,011
James L. Bierman						77,926,307						387,722						32,293						7,527,011
Roy Blunt						77,882,738						431,663						31,921						7,527,011
Richard W. Fisher						77,904,115						409,618						32,589						7,527,011
Meghan M. FitzGerald						77,624,893						691,419						30,010						7,527,011
Cecil D. Haney						77,887,930						401,532						56,860						7,527,011
Christopher S. Lynch						77,995,490						318,301						32,531						7,527,011
Richard J. Mark						77,978,174						334,968						33,180						7,527,011
Tammy Romo						75,980,163						2,335,099						31,060						7,527,011
Stephen H. Rusckowski						77,992,021						321,640						32,661						7,527,011
Nadja Y. West						77,762,668						529,830						53,824						7,527,011

2.    The Company’s shareholders approved, on an advisory basis, the Company’s executive compensation:

FOR						AGAINST						ABSTAIN						BROKER NON-VOTES
72,929,010						5,362,708						54,604						7,527,011

3.    The Company’s shareholders approved the ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2025:

FOR						AGAINST						ABSTAIN						BROKER NON-VOTES
85,288,950						538,057						46,326						—

4.    The shareholder proposal requesting a report on strategies and programs for improving maternal health outcomes did not pass.

FOR						AGAINST						ABSTAIN						BROKER NON-VOTES
3,845,664						73,121,521						1,379,137						7,527,011

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						TENET HEALTHCARE CORPORATION
Date: May 27, 2025			By:			/s/ THOMAS ARNST
						Name: Thomas Arnst
						Title: Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary